More PYC Therapeutics Limited news
PYC Therapeutics LimitedASX: PYC

CEO letter and Operational Update

Jan 16, 2019 at 9:43 PM EST · Issued by PYC Therapeutics Limited

Filed with ASX · Jan 16, 2019 at 9:43 PM EST

On 6ix: 6ix.com/news/ceo-letter-and-operational-update

Pyc Therapeutics Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

PYC Therapeutics Limited on 6ix

Story so far

  • CEO UpdateJul 9, 2018
  • CEO and CSO AppointmentsJun 19, 2017
  • Chief Executive Officer ResignationJul 18, 2016

Earlier from PYC Therapeutics

  • In Vivo Success - peptide vaccine (Amended Graphics)Dec 6, 2018
  • In vivo success - peptide vaccine in Herpes Simplex VirusDec 6, 2018
  • Successful Delivery of CRIPR/Cas9 into Cells ex vivoDec 3, 2018
  • FNA PresentationNov 22, 2018
  • AGM Company PresentationNov 16, 2018

Later from PYC Therapeutics

  • Dec 2018 Operational Update and App4CJan 31, 2019
  • First Competitive Read Out - Peptide VaccineFeb 8, 2019
  • Flagship Program - Successful Animal ModelsMar 11, 2019
  • Collaboration Agreement - siRNA deliveryMar 13, 2019
  • March 2019 Quarterly Operational Update and App4CApr 29, 2019
All PYC Therapeutics news releases↗

Follow PYC Therapeutics into a list and get an email when it puts out news.

Follow PYC Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer